

# Inhaled Levodopa (Inbrija)

## Criteria for Use

### January 2020

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

*The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.*

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at the [PBM INTERnet](#) or [PBM INTRAnet](#) site for further information.

## Exclusion Criteria

If ANY criterion below is met, then the patient should NOT receive inhaled levodopa.

- Concomitant use of a nonselective monoamine oxidase inhibitor (MAOI), such as phenelzine or tranylcypromine (must be >14 days post discontinuing therapy)
- Asthma or chronic obstructive pulmonary disease (COPD)
- Presence of psychotic disorder
- Glaucoma with uncontrolled intraocular pressure (IOP)

## Inclusion Criteria

The answers to all of the following must be fulfilled in order to meet criteria.

- Patient is under the care of a VA/VA-authorized Neurologist or locally designated expert who is responsible for prescribing and monitoring therapy
- Patient has Parkinson's Disease and is receiving at least four times daily carbidopa/levodopa
- Patient will continue to receive oral carbidopa/levodopa therapy
- Patient has OFF time of  $\geq 2$  hours/day
- Contraindication to or inadequate therapeutic response to use of a dopamine agonist, catechol-O-methyl transferase [COMT] inhibitor, monoamine oxidase type B [MAO B] inhibitor, ER capsule formulation or CR tablet formulation.
- Attempts to reduce dosing intervals have not adequately resolved OFF periods

---

Prepared: January 2020. Contact: Kathryn Tortorice Pharm D BCPS, National Clinical Pharmacy Program Manager, VA Pharmacy Benefits Management Services 10P4P

---